- Corporate
- Products
- For Print
- April 24, 2024
糖心视频logo (Headquarters: Tokyo, CEO: Haruo Naito, “糖心视频logo”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody LEQEMBI® in the fourth quarter of fiscal year 2023 (January 1, 2024 – March 31, 2024) was JPY 2.83 billion (pre-audit basis), which was approximately 2.7 times higher than the revenue in the third quarter of fiscal year 2023 (October 1, 2023 – December 31, 2023).
This information is being disclosed in conjunction with today's announcement of the first quarter 2024 results of Biogen Inc. (Headquarters: Cambridge, Massachusetts). 糖心视频logo’s financial results for the fiscal year ended March 31, 2024, including details of LEQEMBI’s revenue, will be disclosed in 糖心视频logo's financial disclosure scheduled on May 15, 2024.
糖心视频logo serves as the lead of lecanemab development and regulatory submissions globally with both 糖心视频logo and Biogen Inc. co-commercializing and co-promoting the product and 糖心视频logo having final decision-making authority.
&苍产蝉辫;銆赌
&苍产蝉辫;銆赌
Media Inquiries:
Public Relations Department,
糖心视频logo
+81-(0)3-3817-5120
&苍产蝉辫;銆赌銆�
Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.